美沙拉嗪联合参苓白术散治疗溃疡性结肠炎的效果观察

The clinical efficacy of mesalazine combined with Shenlingbaizhu powder in treatment of ulcerative colitis

目的观察美沙拉嗪联合参苓白术散散治疗溃疡性结肠炎(UC)的临床疗效。方法将2017年5月至2019年5月符合条件的UC患者120例随机分为对照组和观察组,每组60例。对照组60例给予美沙拉嗪肠溶片口服。观察组60例采用美沙拉嗪肠溶片口服联合参苓白术散口服加保留灌肠。2组均治疗8周。观察比较2组治疗前后的血清炎性因子白细胞介素(IL-6、IL-8)、肿瘤坏死因子(TNF-α)及2组治疗前后Mayo评分、结肠镜评分(Azzolini评分)等指标的变化,并观察临床疗效、复发率及不良反应。结果2组治疗后的血清IL-6、IL-8、TNF-α含量均较治疗前降低,且观察组下降程度较对照组更明显(P<0.05);2组Mayo评分、Azzolini评分、均较治疗前降低,且观察组治疗后的评分较对照组明显降低(P<0.05);观察组的缓解率及总有效率均显著高于对照组(P<0.05);且观察组复发率较对照组低(P<0.05);2组均无明显不良反应,且不良反应发生率差异无统计学意义(P>0.05)。结论美沙拉嗪联合参苓白术散治疗溃疡性结肠炎能减轻炎性反应,疗效确切,不良反应较少,复发率较低。

Objective To investigate the clinical efficacy of mesalazine combined with Shenlingbaizhu powder in treatment of ulcerative colitis(UC).Methods A total of 120 patients with UC who were treated in our hospital from May 2017 to May 2019 enrolled in the study,who were randomly divided into control group and treatment group,with 60 cases in each group.The patients in control group were treated by oral mesalazine enteric coated tablets,however,the patients in observation group,on the basis of control group,were treated by Shenlingbaizhu powder and retention enema,with a treatment course of 8 weeks for both groups.The changes of inflammatory factors(IL-6,IL-8,TNF-α)in serum,the Mayo score,Azzolini score before and after treatment,as well as clinical efficacy,recurrence rate and adverse reactions were observed and compared between the two groups.Results After treatment,the serum levels of IL-6,IL-8,TNF-αin both groups were significantly decreased,moreover,the decrease degree in observation group was more significant than that in control group(P<0.05).And Mayo scores and Azzolini scores in both groups were significantly decreased,moreover,which in observation group were significantly lower than those in control group(P<0.05).In addition the remission rate and total effective rate in observation group were significantly higher than those in control group(P<0.05),but the recurrence rate in observation group was significantly lower than that in control group(P<0.05).Moreover no obvious adverse reactions were found in both groups,and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The mesalazine combined with Shenlingbaizhu powder can relieve the inflammatory reaction in patients with ulcerative colitis,with obvious curative effects,fewer adverse reaction and relapse rate.